Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focused on creating value for people living with severe diseases in immunology and neurology.
We work with stakeholders to address the unmet needs of patients and caregivers, helping them to achieve their goals and to live the lives they want. UCB is on a journey to become the patient-preferred biopharma leader by delivering medicines and solutions that improve lives. Our commitment to value is a promise to bring together the talent, expertise, tools and scientific know-how required to serve patients in need.
At UCB, we take our responsibility
to the planet very seriously.
UCB Ventures, our strategic corporate venture fund established in 2017
Twitter Feed
-
We are returning home from #EULAR2019 feeling inspired by the work that has gone into advancing the #immunology field. We look forward to ongoing collaboration and partnership. See you in Frankfurt! https://t.co/Lh2awHBI3o
— UCB News (@ucb_news) 15.06.2019 -
Delays in nr-axSpA diagnosis make it difficult for patients to receive appropriate treatment early on. #axSpA #EULAR2019 https://t.co/BEi1MmQjrd
— UCB News (@ucb_news) 14.06.2019 -
It's been a busy few days at #EULAR2019 and #WCD2019! Visit our website to find out more: https://t.co/CnItqTpuTA https://t.co/UZeexyC85A
— UCB News (@ucb_news) 14.06.2019
